Newsroom

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share FIRST TRUST BLOOMBERG GLOBAL SEMICONDUCTOR SUPPLY CHAIN UCITS ETF 09.01.2026 CHPS.LN IE000KXTLDE2  500,002.00 USD  16,211,680.64   32.423  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Alerian Disruptive Technology Real Estate UCITS ETF 09.01.2026 LANDXEN.LN IE000C75IMX8 22,412.00 USD 421,330.26 18.799  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Alerian Disruptive Technology Real Estate UCITS ETF 09.01.2026 LANDXN.LN IE000RN036E0 28,035.00 USD 573,941.15 20.472  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Indxx Global Aerospace & Defence UCITS ETF 09.01.2026 MISL.LN IE000NVDQXE1 3,050,002.00 USD 109,626,881.42   35.943  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Indxx Innovative Transaction & Process UCITS ETF 09.01.2026 LEGR LN IE00BF5DXP42 1,025,002.00 USD 51,223,621.92 49.974  ...

SALT LAKE CITY--(BUSINESS WIRE)--USANA Health Sciences, Inc. (NYSE: USNA) today announced preliminary fiscal year 2025 net sales and initial net sales guidance for fiscal year 2026 ahead of its presentation at the 28th Annual ICR Conference. At the conference, Doug Hekking, CFO, and Walter Noot, COO, will discuss USANA’s strategy, including the Company’s initial fiscal year 2026 sales outlook. Preliminary Fiscal Year 2025 Net Sales Results The Company currently anticipates fiscal year 2025 cons...

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has entered into a clinical trial collaboration with GSK plc (“GSK”, LSE/NYSE: GSK) to evaluate ivonescimab, a novel, investigational PD-1 / VEGF bispecific antibody, in combination with risvutatug rezetecan (also known as GSK’227), GSK’s novel investigational B7-H3 targeting antibody drug conjugate (ADC), across multiple solid tumor settings, including small cell lung cancer (SCLC). “We believe exploring new mec...

LONDON--(BUSINESS WIRE)--  09-January-2026 Issue: Newday Funding Master Issuer Plc SERIES 2024-2 Class A 144A XS2834466976 Pursuant to our appointment as Agent for the above stated issue, please be advised of the following interest rate determination: Date From: 15-December-2025 Date To: 15-January-2026 Record Date: 14-January-2026 Value Date: 15-January-2026 Benchmark Rate: 3.84354% Margin: 0.9% Total Rate: 4.74354% Number of Days: 31 Day Count: Actual / 365L Interest Frequency: Monthly Total...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest Nasdaq-100 Moderate Buffer UCITS ETF - September 09.01.2026 QSEP.LN IE000FQ808R5  450,002.00 USD  10,385,212.09   23.078  ...

LONDON--(BUSINESS WIRE)--    Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust NASDAQ Clean Edge Green Energy UCITS ETF 09.01.2026 QCLN.LN IE00BDBRT036 600,002.00 USD 11,173,110.76 18.622  ...